Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

A method of inhibiting cell proliferation associated with the expression of EGFRvIII, comprising treating cells expressing EGFRvIII with an effective amount of an antibody or fragment there of, wherein said antibody or fragment thereof binds to EGFRvIII and wherein the antibody comprises a heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequence of antibody 13.1.2 (SEQ ID NO:

• 138), 131 (SEQ ID NO:
• 2), 170 (SEQ ID NO:
• 4), 150 (SEQ ID NO:
• 5), 095 (SEQ ID NO:
• 7), 250 (SEQ ID NO:
• 9), 139 (SEQ ID NO:
• 10), 211 (SEQ ID NO:
• 12), 124 (SEQ ID NO:
• 13), 318 (SEQ ID NO:
• 15), 342 (SEQ ID NO:
• 16), and 333 (SEQ ID NO:
• 17).

A method of inhibiting cell proliferation associated with the expression of EGFRvIII, comprising treating cells expressing EGFRvIII with an effective amount of an isolated antibody that binds to EGFRvIII and that comprises a heavy chain amino acid sequence comprising the following complementarity determining regions (CDRs):

• (a) CDR1 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR1 region of antibodies 13.1.2 (SEQ ID NO:
• 138), 131 (SEQ ID NO:
• 2), 170 (SEQ ID NO:
• 4), 150 (SEQ ID NO:
• 5), 095 (SEQ ID NO:
• 7), 250 (SEQ ID NO:
• 9), 139 (SEQ ID NO:
• 10), 211 (SEQ ID NO:
• 12), 124 (SEQ ID NO:
• 13), 318 (SEQ ID NO:
• 15), 342 (SEQ ID NO:
• 16), and 333 (SEQ ID NO:
• 17);
• (b) CDR2 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR2 region of antibodies 13.1.2 (SEQ ID NO:
• 138), 131 (SEQ ID NO:
• 2), 170 (SEQ ID NO:
• 4), 150 (SEQ ID NO:
• 5), 095 (SEQ ID NO:
• 7), 250 (SEQ ID NO:
• 9), 139 (SEQ ID NO:
• 10), 211 (SEQ ID NO:
• 12), 124 (SEQ ID NO:
• 13), 318 (SEQ ID NO:
• 15), 342 (SEQ ID NO:
• 16), and 333 (SEQ ID NO:
• 17);
• and
• (c) CDR3 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR3 region of antibodies 13.1.2 (SEQ ID NO:
• 138), 131 (SEQ ID NO:
• 2), 170 (SEQ ID NO:
• 4), 150 (SEQ ID NO:
• 5), 095 (SEQ ID NO:
• 7), 250 (SEQ ID NO:
• 9), 139 (SEQ ID NO:
• 10), 211 (SEQ ID NO:
• 12), 124 (SEQ ID NO:
• 13), 318 (SEQ ID NO:
• 15), 342 (SEQ ID NO:
• 16), and 333 (SEQ ID NO:
• 17).

A method of inhibiting cell proliferation associated with the expression of EGFRvIII, comprising treating cells expressing EGFRvIII with an effective amount of an isolated antibody that binds to EGFRvIII and that comprises a light chain amino acid sequence comprising the following complementarity determining regions (CDRs):

• (a) CDR1 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR1 region of antibodies 13.1.2, 131, 170, 150, 123, 095, 139, 250, 211, 318, 342, and 333 as identified in SEQ ID NO:
• 140, 19, 20, 21, 29, 23, 25, 26, 28, 33, 31 and 32;
• (b) CDR2 consisting of a sequence selected from the group consisting of amino acid sequences for the CDR1 region of antibodies 13.1.2, 131, 170, 150, 123, 095, 139, 250, 211, 318, 342, and 333 as identified in SEQ ID NO:
• 140, 19, 20, 21, 29, 23, 25, 26, 28, 33, 31 and 32;
• and
• (c) CDR3 consisting of a sequence selected from the group consisting of amino acid sequences for the CDR1 region of antibodies 13.1.2, 131, 170, 150, 123, 095, 139, 250, 211, 318, 342, and 333 as identified in SEQ ID NO:
• 140, 19, 20, 21, 29, 23, 25, 26, 28, 33, 31 and 32.